Xi Cheng

Title: Innovations by Xi Cheng in Tissue Damage Treatment

Introduction

Xi Cheng is an accomplished inventor based in Woodland, CA (US). He has made significant contributions to the field of medical technology, particularly in the treatment of drug-related side effects and tissue damage. His innovative approach focuses on targeting the CD24-HMGB1-Siglec10 axis, which has the potential to revolutionize treatment methods for immune dysregulation.

Latest Patents

Xi Cheng holds a patent for his groundbreaking work titled "Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis." This patent outlines methods and compositions for treating tissue-damage related immune dysregulation. The technology involves administering a composition that includes various components such as CD24, CD24 fragments, HMGB1-binding proteins, and Siglec 10 agonists. This innovative treatment could provide new hope for patients suffering from these conditions.

Career Highlights

Xi Cheng is affiliated with the University of Michigan, where he continues to advance his research and development efforts. His work has garnered attention for its potential impact on medical treatments and patient care. With a focus on innovative solutions, Cheng is dedicated to improving health outcomes through his inventions.

Collaborations

Xi Cheng collaborates with esteemed colleagues, including Guo-Yun Chen and Xincheng Zheng. Their combined expertise enhances the research and development process, fostering an environment of innovation and discovery.

Conclusion

Xi Cheng's contributions to the field of medical technology exemplify the power of innovation in addressing complex health issues. His patent and ongoing research hold promise for improving treatment options for patients facing drug-related side effects and tissue damage.